Compare XPOF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | VNDA |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.4M | 474.0M |
| IPO Year | 2021 | 2005 |
| Metric | XPOF | VNDA |
|---|---|---|
| Price | $5.75 | $8.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $10.06 | ★ $14.90 |
| AVG Volume (30 Days) | 852.8K | ★ 3.7M |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.24 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $11,092,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.50 |
| Revenue Next Year | $5.57 | $38.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $3.83 | $3.81 |
| 52 Week High | $11.14 | $9.91 |
| Indicator | XPOF | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.78 | 56.69 |
| Support Level | $5.65 | $7.39 |
| Resistance Level | $8.90 | $9.35 |
| Average True Range (ATR) | 0.65 | 0.57 |
| MACD | -0.03 | 0.13 |
| Stochastic Oscillator | 40.77 | 49.81 |
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.